Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)
The purpose of this research is to add dasatinib to the standard treatment temozolomide and radiation, to see if this combination is better than the current standard treatment of radiation therapy and temozolomide. This study is for patients with newly diagnosed Glioblastoma Multiforme (GBM). Dasatinib helps to stop signals that cause tumors to grow. Dasatinib is FDA approved for treating certain cancers but is currently not approved for use in treating brain cancer. Therefore the use of dasatinib in this study is considered investigational.
Back to Clinical Trials list